menu
    • menu
    [{"orgOrder":0,"company":"PhoreMost","sponsor":"Oxford Biomedica","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"LentiVector based gene therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"PhoreMost","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PhoreMost \/ Oxford Biomedica","highestDevelopmentStatusID":"2","companyTruncated":"PhoreMost \/ Oxford Biomedica"},{"orgOrder":0,"company":"PhoreMost","sponsor":"Vipergen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"PhoreMost","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PhoreMost \/ PhoreMost","highestDevelopmentStatusID":"3","companyTruncated":"PhoreMost \/ PhoreMost"},{"orgOrder":0,"company":"PhoreMost","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Protein","graph1":"Oncology","graph2":"Discovery","graph3":"PhoreMost","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"PhoreMost \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"PhoreMost \/ Roche"}]

    Find Clinical Drug Pipeline Developments & Deals by PhoreMost

    Menu

    PhoreMost

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PhoreMost

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            PhoreMost

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            PhoreMost Enters Multi-Project Drug Target Discovery Collaboration with Roche

                            Details : Novel targets identified will be further validated and characterised by Roche’s R&D organisation, and any SITESEEKER-based probes would become the starting point for drug discovery efforts across a set of disease pathways in immunology and haematology.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 06, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PhoreMost

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            PhoreMost

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Vipergen

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Vipergen Establishes Research Partnership with Phore Most Focused on Dna Encoded Library (DEL)-Based Drug Disc...

                            Details : Under the terms of the agreement Vipergen will apply its leading technologies for DNA-encoded library synthesis and screening including DEL technology platforms to identify novel small-molecule compounds that bind to selected PhoreMost protein targets.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 14, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Vipergen

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PhoreMost

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            PhoreMost

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LentiVector based gene therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Oxford Biomedica

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            PhoreMost, Oxford Biomedica Enter Discovery Collaboration for Next-Gen CAR-T Therapies

                            Details : PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, to identify therapeutic candidates for Oxford Biomedica’s LentiVector® gene therapy delivery system.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            November 09, 2020

                            Lead Product(s) : LentiVector based gene therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Oxford Biomedica

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth